[go: up one dir, main page]

HK1038313A1 - Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding - Google Patents

Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding Download PDF

Info

Publication number
HK1038313A1
HK1038313A1 HK01109049.1A HK01109049A HK1038313A1 HK 1038313 A1 HK1038313 A1 HK 1038313A1 HK 01109049 A HK01109049 A HK 01109049A HK 1038313 A1 HK1038313 A1 HK 1038313A1
Authority
HK
Hong Kong
Prior art keywords
antibody
antigen
binding fragment
vla
cells
Prior art date
Application number
HK01109049.1A
Other languages
German (de)
English (en)
French (fr)
Chinese (zh)
Other versions
HK1038313B (en
Inventor
Gregory R. Mundy
Toshiyuki Yoneda
Original Assignee
Board Of Regents, The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Board Of Regents, The University Of Texas System filed Critical Board Of Regents, The University Of Texas System
Publication of HK1038313A1 publication Critical patent/HK1038313A1/en
Publication of HK1038313B publication Critical patent/HK1038313B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70542CD106
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Photoreceptors In Electrophotography (AREA)
HK01109049.1A 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding HK1038313B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10018298P 1998-09-14 1998-09-14
US100182P 1998-09-14
PCT/US1999/021170 WO2000015247A2 (en) 1998-09-14 1999-09-13 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists

Publications (2)

Publication Number Publication Date
HK1038313A1 true HK1038313A1 (en) 2002-03-15
HK1038313B HK1038313B (en) 2009-05-22

Family

ID=

Also Published As

Publication number Publication date
KR100628818B1 (ko) 2006-09-27
ZA200102032B (en) 2002-11-07
CA2343579C (en) 2012-05-29
US7211252B2 (en) 2007-05-01
IL197686A0 (en) 2011-07-31
JP2002524529A (ja) 2002-08-06
EP1113810A2 (en) 2001-07-11
ES2319831T3 (es) 2009-05-12
US20020022028A1 (en) 2002-02-21
CZ2001916A3 (cs) 2001-08-15
SK6052001A3 (en) 2001-12-03
SI1113810T1 (sl) 2009-04-30
WO2000015247A8 (en) 2009-12-23
NO327855B1 (no) 2009-10-05
ATE418999T1 (de) 2009-01-15
NZ511062A (en) 2003-04-29
IL141877A0 (en) 2002-03-10
PL347128A1 (en) 2002-03-25
PL203114B1 (pl) 2009-08-31
JP5378303B2 (ja) 2013-12-25
EA004270B1 (ru) 2004-02-26
HU229038B1 (hu) 2013-07-29
WO2000015247A2 (en) 2000-03-23
JP2013241441A (ja) 2013-12-05
BR9913705A (pt) 2001-06-05
CZ302997B6 (cs) 2012-02-15
AU6248699A (en) 2000-04-03
AU757873B2 (en) 2003-03-06
HUP0103630A2 (hu) 2002-01-28
EE200100146A (et) 2002-06-17
CY1109413T1 (el) 2014-08-13
CN1321091A (zh) 2001-11-07
CN1236815C (zh) 2006-01-18
TR200100734T2 (tr) 2001-07-23
EP1113810B1 (en) 2008-12-31
CA2343579A1 (en) 2000-03-23
WO2000015247A3 (en) 2000-05-25
NO20011283D0 (no) 2001-03-14
DE69940206D1 (de) 2009-02-12
IS5856A (is) 2001-02-23
NO20011244L (no) 2001-05-14
KR20010085793A (ko) 2001-09-07
IS2631B (is) 2010-06-15
PT1113810E (pt) 2009-03-10
JP2010235620A (ja) 2010-10-21
HUP0103630A3 (en) 2004-03-01
NO20011244D0 (no) 2001-03-12
DK1113810T3 (da) 2009-04-06
EP2065050A1 (en) 2009-06-03
EA200100362A1 (ru) 2001-12-24
SK287601B6 (sk) 2011-03-04
EE05558B1 (et) 2012-08-15

Similar Documents

Publication Publication Date Title
EP1113810B1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
BG66149B1 (bg) Използване на антитяло хомолог като антагонист на интегрин алфа-4 субединица за получаване на фармацевтичен състав за лечение на фиброзни състояния
US20100183599A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US20140234299A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
US20020041874A1 (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
HK1038313B (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
HK1131560A (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
MXPA01002670A (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP1700606A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
HK1094948A (en) Therapies for chronic renal failure using one or more integrin antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150913